Vion wieder da!
Seite 1 von 1 Neuester Beitrag: 11.05.07 14:18 | ||||
Eröffnet am: | 17.08.05 10:48 | von: RLDJA | Anzahl Beiträge: | 8 |
Neuester Beitrag: | 11.05.07 14:18 | von: Ethos | Leser gesamt: | 1.508 |
Forum: | Börse | Leser heute: | 2 | |
Bewertet mit: | ||||
Zudem weisst das Unternehmen mit geringen Verlusten,
optimistische Zahlen für das 2. Quartal 2005 aus.
NEW HAVEN, CT, August 5, 2005 – VION PHARMACEUTICALS, INC. (NASDAQ
SMALLCAP: VION) today announced results for the second quarter and six-month period
ended June 30, 2005.
The Company reported a net loss of $5.1 million, or $0.08 per share, for the three-month period ended June 30, 2005, compared to a net loss of $3.7 million, or $0.07 per share, for the same period in 2004. Weighted-average common shares outstanding for the three months ended June 30, 2005 and 2004 were 65.9 million and 55.3 million, respectively. Total operating expenses were $5.6 million and $3.9 million for the three months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to costs associated with the Company’s preclinical product development and higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE (VNP40101M) initiated in March 2005.
For the six-month period ended June 30, 2005, the net loss was $9.7 million, or $0.15 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same period in 2004. Weighted-average common shares outstanding for the six months ended June 30, 2005 and 2004 were 64.3 million and 51.3 million, respectively. Total operating expenses were $10.5 million and $7.3 million for the six months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE(VNP40101M) initiated in March 2005, and costs associated with the Company’s preclinical product development.
The Company reported ending the quarter with $62.3 million in cash and cash equivalents.
Vion Pharmaceuticals, Inc. is developing anticancer agents. Vion has two agents in clinical trials: CLORETAZINE™ (VNP40101M), a unique sulfonylhydrazine alkylating agent, is being valuated in five clinical trials, including a Phase III trial in combination with Ara-C in relapsed acute myelogenous leukemia, and Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in combination with gemcitabine in a Phase II trial in pancreatic cancer and additional clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is evaluating KS119W,
a hypoxia-selective compound from the sulfonylhydrazine class,
and heterocyclic hydrazones. The Company is also seeking development partners for TAPET®, its modified Salmonella vector used to deliver anticancer agents directly to umors.
Das sich für AML (Akute Myeloischer Leukämie) in Erprobung befindliche Medikament Cloretazine/VNP40101M wird nun in den USA in einer Phase-III-Studie untersucht. Vion kündigte an, dass die ersten Patienten mit der Einnahme des Medikaments begonnen haben. Diese Patientengruppe hatten zuvor einen Rückfall von Akuter Myeloischer Leukämie erlitten
Hierbei handelt es sich um RCM CAPITAL MANAGEMENT, die nach diesem Zukauf von 863.000 Shares mittlerweile insgesamt bereits 2.047.920 Stücke in ihren Depots horten.
Gegenüber dem bereits im Vorfeld dieses Kaufes gehaltenem Bestand wurde also nochmals um 72,84% aufgestockt!
Quelle: Nasdaq-Info
Die Analysten von Wedbush Morgan Securities stufen die Aktie von Vion Pharmaceuticals (ISIN US9276241067/ WKN 902972) in einer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei 4 USD.
Analyse-Datum: 20.06.2005